AbbVie is sued for using Humira patent deals to block competition STAT
The patent deals restrict the other drug makers from selling biosimilar versions of Humira in the U.S. until 2023, but sales are permitted in Europe.
AbbVie is sued for using Humira patent deals to block competition STAT
The patent deals restrict the other drug makers from selling biosimilar versions of Humira in the U.S. until 2023, but sales are permitted in Europe.